Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890445853> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2890445853 abstract "TPS10576 Background: CUDC-907 is an oral first-in-class small molecule inhibitor of histone deacetylases (HDACs) and phosphatidylinositol-3-kinases (PI3Ks), two enzyme classes commonly implicated in pediatric malignancies. Preclinical data demonstrate that inhibition of these enzymes decreases tumor growth across a range of histologies. Data from preclinical and clinical studies suggest that down-regulation of Myc or Mycn signaling may be important in the antineoplastic effects of CUDC-907. Myc or Mycn signaling appears to drive a number of pediatric cancers, heralds a poor prognosis in many of these diseases and has proven difficult to target. CUDC-907 has completed adult phase I testing in patients with hematologic malignancies. The drug was tolerable using a 5 days on/2 days off (5/2) dosing strategy, with a recommended phase II dose of 60 mg. Diarrhea, fatigue, nausea and thrombocytopenia were the most commonly reported side effects. Partial and complete responses were observed in patients with Myc-altered diffuse large B cell lymphoma. Methods: This study is a phase I, open-label, multicenter trial of CUDC-907 in patients 1-21 years of age with relapsed/refractory solid tumors, brain tumors and lymphomas (NCT02909777). The primary objectives are to determine the recommended phase II dose, describe toxicities, and describe pharmacokinetic parameters of CUDC-907 in this population. Other objectives include evaluation of disease response and exploration of the pharmacodynamic effects of CUDC-907. Patients receive CUDC-907 orally on a 5/2 schedule in 28-day cycles, with a pediatric mini-tab formulation available for younger children. Part A consists of a standard 3+3 design evaluating up to three dose levels. Following dose escalation, Part B consists of two expansion cohorts for patients with Mycn/Myc-driven neuroblastoma or mature B-cell lymphoma. Up to 44 patients may be enrolled across Parts A and B. Detailed pharmacokinetic testing is required in the first two cycles. Optional pharmacodynamic testing will quantify histone acetylation, Myc protein, and phospho-S6 in serial blood samples. Enrollment began in October 2016 and is ongoing. Clinical trial information: NCT02909777." @default.
- W2890445853 created "2018-09-27" @default.
- W2890445853 creator A5000453742 @default.
- W2890445853 creator A5001066329 @default.
- W2890445853 creator A5001861945 @default.
- W2890445853 creator A5003639088 @default.
- W2890445853 creator A5004549843 @default.
- W2890445853 creator A5010485986 @default.
- W2890445853 creator A5023600635 @default.
- W2890445853 creator A5036283202 @default.
- W2890445853 creator A5050738935 @default.
- W2890445853 creator A5053168617 @default.
- W2890445853 creator A5057546890 @default.
- W2890445853 creator A5061303586 @default.
- W2890445853 creator A5069053611 @default.
- W2890445853 creator A5073092034 @default.
- W2890445853 creator A5080466334 @default.
- W2890445853 creator A5089509810 @default.
- W2890445853 date "2017-05-20" @default.
- W2890445853 modified "2023-09-27" @default.
- W2890445853 title "Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma." @default.
- W2890445853 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps10576" @default.
- W2890445853 hasPublicationYear "2017" @default.
- W2890445853 type Work @default.
- W2890445853 sameAs 2890445853 @default.
- W2890445853 citedByCount "0" @default.
- W2890445853 crossrefType "journal-article" @default.
- W2890445853 hasAuthorship W2890445853A5000453742 @default.
- W2890445853 hasAuthorship W2890445853A5001066329 @default.
- W2890445853 hasAuthorship W2890445853A5001861945 @default.
- W2890445853 hasAuthorship W2890445853A5003639088 @default.
- W2890445853 hasAuthorship W2890445853A5004549843 @default.
- W2890445853 hasAuthorship W2890445853A5010485986 @default.
- W2890445853 hasAuthorship W2890445853A5023600635 @default.
- W2890445853 hasAuthorship W2890445853A5036283202 @default.
- W2890445853 hasAuthorship W2890445853A5050738935 @default.
- W2890445853 hasAuthorship W2890445853A5053168617 @default.
- W2890445853 hasAuthorship W2890445853A5057546890 @default.
- W2890445853 hasAuthorship W2890445853A5061303586 @default.
- W2890445853 hasAuthorship W2890445853A5069053611 @default.
- W2890445853 hasAuthorship W2890445853A5073092034 @default.
- W2890445853 hasAuthorship W2890445853A5080466334 @default.
- W2890445853 hasAuthorship W2890445853A5089509810 @default.
- W2890445853 hasConcept C121332964 @default.
- W2890445853 hasConcept C121608353 @default.
- W2890445853 hasConcept C126322002 @default.
- W2890445853 hasConcept C142424586 @default.
- W2890445853 hasConcept C143998085 @default.
- W2890445853 hasConcept C2779338263 @default.
- W2890445853 hasConcept C2993640289 @default.
- W2890445853 hasConcept C502942594 @default.
- W2890445853 hasConcept C535046627 @default.
- W2890445853 hasConcept C71924100 @default.
- W2890445853 hasConcept C87355193 @default.
- W2890445853 hasConceptScore W2890445853C121332964 @default.
- W2890445853 hasConceptScore W2890445853C121608353 @default.
- W2890445853 hasConceptScore W2890445853C126322002 @default.
- W2890445853 hasConceptScore W2890445853C142424586 @default.
- W2890445853 hasConceptScore W2890445853C143998085 @default.
- W2890445853 hasConceptScore W2890445853C2779338263 @default.
- W2890445853 hasConceptScore W2890445853C2993640289 @default.
- W2890445853 hasConceptScore W2890445853C502942594 @default.
- W2890445853 hasConceptScore W2890445853C535046627 @default.
- W2890445853 hasConceptScore W2890445853C71924100 @default.
- W2890445853 hasConceptScore W2890445853C87355193 @default.
- W2890445853 hasLocation W28904458531 @default.
- W2890445853 hasOpenAccess W2890445853 @default.
- W2890445853 hasPrimaryLocation W28904458531 @default.
- W2890445853 hasRelatedWork W1560058309 @default.
- W2890445853 hasRelatedWork W1728255343 @default.
- W2890445853 hasRelatedWork W2077126828 @default.
- W2890445853 hasRelatedWork W2110831740 @default.
- W2890445853 hasRelatedWork W2171285924 @default.
- W2890445853 hasRelatedWork W2211739901 @default.
- W2890445853 hasRelatedWork W2224167961 @default.
- W2890445853 hasRelatedWork W2279314615 @default.
- W2890445853 hasRelatedWork W2317760910 @default.
- W2890445853 hasRelatedWork W2621746631 @default.
- W2890445853 hasRelatedWork W2753243651 @default.
- W2890445853 hasRelatedWork W2763994374 @default.
- W2890445853 hasRelatedWork W2795150236 @default.
- W2890445853 hasRelatedWork W2889035790 @default.
- W2890445853 hasRelatedWork W2890177966 @default.
- W2890445853 hasRelatedWork W2942540574 @default.
- W2890445853 hasRelatedWork W2952496787 @default.
- W2890445853 hasRelatedWork W2956464910 @default.
- W2890445853 hasRelatedWork W3020509754 @default.
- W2890445853 hasRelatedWork W3093290305 @default.
- W2890445853 isParatext "false" @default.
- W2890445853 isRetracted "false" @default.
- W2890445853 magId "2890445853" @default.
- W2890445853 workType "article" @default.